National Institutes of Health

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

The New York Society for the Prevention of Cruelty to Children is a charity that offers counseling, legal, and educational services.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.

Daxor Corporation is a medical device and biotechnology firm based in New York, specializing in blood volume measurement. The company developed the BVA-100 Blood Volume Analyzer, which is the first FDA-approved instrument designed to provide rapid and accurate measurement of a patient's true blood volume. This innovative device is utilized in diagnosing and treating various medical conditions, including congestive heart failure, hypertension, and anemia, among others. Daxor also offers additional services such as semen banking, blood storage, and laboratory testing. The company has established a cooperative research agreement with the Uniformed Services University of the Health Sciences to study the efficacy of the BVA-100 in assessing blood volume in traumatic injury contexts. Founded in 1970 and originally known as Idant Corporation, Daxor Corporation has positioned itself at the forefront of medical instrumentation technology.

Columbia University, a prestigious research institution and Ivy League school in New York City, is dedicated to advancing knowledge across all disciplines. It manages its endowment through the Columbia Investment Management Company (IMC), a wholly-owned subsidiary established in 2002. The IMC, led by an executive management team, oversees the bulk of the university's endowment, excluding real estate holdings and certain charitable giving vehicles. The earnings from these investments support various academic and public service programs, including scholarships, professorships, fellowships, and basic research. The university's endowment is ultimately governed by the board of trustees.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

The Mount Sinai School of Medicine in New York, New York, one of the only schools in the nation with a distinctive Department of Medical Education that continually improves the quality of its teaching, offers students a variety of medical academics to shape them into compassionate assistants, professionals and industry leaders. The academics available at Mount Sinai include master's and PhD programs in areas like: * Science and Medicine * Patient Oriented Research Training and Leadership * Biomedical Sciences * Genetic Counseling * Clinical Research Besides its degree-granting programs, Mount Sinai also offers an extensive number of residencies and fellowships, some of which include: * Anesthesiology * Cardiology * Dental Medicine * Emergency Medicine * Hematology and Oncology College life at Mount Sinai is fully-immersed in the medical sciences. All your instruction, provided by medical professionals, will be delivered in a hospital setting, allowing you to familiarize yourself with the many resources and technology used in today's hospitals. Mount Sinai is also home to the Levy Library, which is fully-stocked with myriad medical resources, from journals to professional magazines to textbooks. Since each program has different admissions requirements, please contact Mount Sinai for more information on a program that interests you and your career goals. Tuition assistance is available to students through fellowship programs and Mount Sinai grants and scholarships. For more information federal sources of financial aid, please contact an aid advisor from the school.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Simulations Plus is a developer of specialized software focused on Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) as well as Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation. Founded in 1996 and headquartered in Lancaster, California, the company serves various sectors, including pharmaceuticals, biotechnology, chemicals, cosmetics, and food ingredients. Its software enables pharmaceutical scientists to predict key endpoints and dynamics in silico, effectively lowering research and development costs while facilitating informed decision-making. Simulations Plus employs over 60 individuals and has a consulting team based in Buffalo, New York. The company’s technology is licensed by 19 of the top 20 pharmaceutical companies, along with a range of mid-sized and smaller firms, as well as major regulatory agencies. Additionally, trusted distributors manage sales and scientific support in Asian markets.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

NYU Langone Health is a nonprofit academic medical center located in New York City, recognized for its commitment to patient-centered care, research, and medical education. The organization offers a comprehensive range of healthcare services, diagnosing and treating various conditions, including lung diseases, joint and muscle disorders, neurological disorders, blood disorders, and gastrointestinal issues. As a center of excellence, NYU Langone Health integrates advanced medical practices with innovative research to enhance patient outcomes and contribute to advancements in healthcare.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Akelos, Inc. is a biopharmaceutical company based in New York, focusing on the development of novel non-narcotic drugs aimed at treating neuropathic pain. Founded in 2018, the company is dedicated to addressing the opioid epidemic by creating alternatives to opioid therapies. Currently, Akelos is advancing two drug candidates through pre-clinical development stages. Additionally, the company has initiated a research collaboration to develop and commercialize a unique non-opioid anti-hyperalgesic drug specifically designed for chronic and neuropathic pain management. Akelos strives to tackle significant unmet medical needs in pain management through innovative scientific approaches.

POP Biotechnologies is a life sciences company based in Buffalo, NY, focused on enhancing individual health through innovative nanomedicine solutions. The company develops targeted therapies aimed at treating cancer and other serious diseases, utilizing advanced nanoparticle-based drug delivery systems. Their proprietary technology allows for the precise release of drug payloads when activated by near-infrared light, providing healthcare providers with effective tools to address patient needs in oncology and infectious diseases.

Quadrant Biosciences Inc. is a life sciences company focused on developing epigenetic diagnostic solutions and biomarker technologies aimed at addressing significant healthcare challenges, particularly in the early identification of neurological disorders such as Autism Spectrum Disorder, concussion, and Parkinson's Disease. Founded in 2015 and based in Syracuse, New York, the company has established collaborative research relationships with various institutions to explore innovative diagnostic and therapeutic solutions. Quadrant Biosciences leverages its expertise in RNA analysis to enhance healthcare delivery and has also contributed to addressing health issues related to the COVID-19 pandemic. The company aims to improve lives through its commitment to advancing molecular diagnostic tools.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

Soterix Medical is a New York-based company that specializes in developing medical devices and accessories centered on neuromodulation and brain stimulation technologies. Founded by Abhishek Datta, the company focuses on products that include brain stimulation and transcranial electrical stimulation (tES), as well as high-definition transcranial electrical stimulation (HD-tES). Soterix Medical aims to provide safe, effective, and user-friendly neuromodulation solutions for clinicians and patients.

TheraSource is a growing biotech company founded in 2004 and located in the Greater New York area. Our mission is to develop novel anti-inflammatory therapeutics for the treatment of human diseases. Our founder and scientists have demonstrated the efficacy of several newly-discovered molecules in preclinical studies of various medical conditions including ischemic acute kidney injury (AKI), inflammatory bowel disease (IBD), acute ischemic stroke, acute radiation syndrome, shock and sepsis, leading to >250 peer-reviewed publications.

Roswell Park Cancer Institute (RPCI), established in 1898 by Dr. Roswell Park, is recognized as America's first cancer center. It pioneered a multidisciplinary approach to cancer treatment, emphasizing collaboration between scientists and clinicians, which has become the benchmark for modern comprehensive cancer centers. RPCI is one of the few facilities in upstate New York designated as a "comprehensive cancer center" by the National Cancer Institute and is a member of the National Comprehensive Cancer Network (NCCN). Faculty at RPCI are actively involved in developing Clinical Practice Guidelines in Oncology™, which are the internationally recognized standards for oncology clinical policy and are continually updated to reflect the latest advancements in cancer treatment.

Shade is a New York-based company that designs and develops advanced wearable ultraviolet measuring technology aimed at patients with lupus, skin cancer, and diabetes. Its primary product, an ultra-sensitive wearable UV sensor, provides real-time and accurate measurements of UV exposure based on clinical evidence. The sensor is designed to determine the daily threshold of UV exposure relevant to dermatological care, particularly for photosensitive diseases. By delivering timely notifications, the device empowers patients to make informed decisions about sun exposure, helping them manage their health effectively. Shade's development has received support from the National Cancer Institute and the National Science Foundation, underscoring its commitment to enhancing patient care through innovative technology.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

Roswell Park Cancer Institute (RPCI), established in 1898 by Dr. Roswell Park, is recognized as America's first cancer center. It pioneered a multidisciplinary approach to cancer treatment, emphasizing collaboration between scientists and clinicians, which has become the benchmark for modern comprehensive cancer centers. RPCI is one of the few facilities in upstate New York designated as a "comprehensive cancer center" by the National Cancer Institute and is a member of the National Comprehensive Cancer Network (NCCN). Faculty at RPCI are actively involved in developing Clinical Practice Guidelines in Oncology™, which are the internationally recognized standards for oncology clinical policy and are continually updated to reflect the latest advancements in cancer treatment.

Kitware develops and supports open-source software in the fields of computer vision, medical imaging, visualization, 3D data publishing, and technical software development. Its solutions include Insight Segmentation and Registration Toolkit, an open-source software system to support the VisibleHuman project; CMake, a cross-platform open-source make system to control the software compilation process using platform and compiler independent configuration files; Visualization ToolKit, an open source software system for 3D computer graphics, image processing, and visualization for researchers and developers around the world; KiwiViewer, an interactive application for the exploration of geometric datasets on multi-touch mobile devices; and MIDAS, a multi-media server for storing scientific data and related metadata reports. The company also provides ActiViz, which provides an interface to the Visualization Toolkit, an object-oriented interface that encompasses various algorithms to transform data into interactive 3D environments; VolView, an interactive system for volume visualization that allows researchers to explore and analyze 3D medical or scientific data on Windows and Unix platforms; CDashPro, a dashboard hosting service that aggregates, analyzes, and displays the results of software testing processes; and ParaViewPro, a professional support subscription for the ParaView scientific visualization application. Kitware was founded in 1998 and is based in Clifton Park, New York.

Noom, Inc. is a New York-based company that specializes in mobile health coaching through a psychology-based digital health platform. Founded in 2008, Noom develops a mobile application that combines evidence-based curricula, personalized coaching, and data-driven insights to help users achieve their health and wellness goals, including weight management and chronic disease prevention. The platform offers scalable tools for exercise and nutrition coaching, utilizing artificial intelligence to facilitate behavioral change. Recognized for its innovative approach, Noom has received multiple grants from the National Institutes of Health and was the first mobile application certified by the Centers for Disease Control as a diabetes prevention program. The company also caters to business enterprises, supporting organizations in promoting employee health. With additional offices in Seoul and Tokyo, Noom continues to expand its global reach and impact on personal health management.

Roswell Park Cancer Institute (RPCI), established in 1898 by Dr. Roswell Park, is recognized as America's first cancer center. It pioneered a multidisciplinary approach to cancer treatment, emphasizing collaboration between scientists and clinicians, which has become the benchmark for modern comprehensive cancer centers. RPCI is one of the few facilities in upstate New York designated as a "comprehensive cancer center" by the National Cancer Institute and is a member of the National Comprehensive Cancer Network (NCCN). Faculty at RPCI are actively involved in developing Clinical Practice Guidelines in Oncology™, which are the internationally recognized standards for oncology clinical policy and are continually updated to reflect the latest advancements in cancer treatment.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

AccuVein Inc. is a manufacturer of vein visualization solutions aimed at enhancing clinical care for healthcare professionals. Founded in 2006 and based in Medford, New York, the company specializes in portable, non-contact devices that enable practitioners to visualize peripheral veins on a patient's skin. Its flagship product, the AV400, utilizes proprietary technology to assist in locating veins for various medical procedures, including IV access, blood draws, and cosmetic injections. AccuVein also offers a range of products, including hands-free and wheeled solutions, to cater to different medical settings such as surgery centers, imaging centers, and long-term care facilities. The company's products are distributed through a network of sales representatives and distributors both domestically and internationally.

Diffinity Genomics, Inc. is a biotechnology company based in West Henrietta, New York, that specializes in developing single-use disposable products for nucleic acid isolation and analysis in the life sciences sector. Founded in 2005, the company offers a range of products, including RapidTip, a functional pipette tip designed for purifying polymerase chain reaction (PCR) amplicons, and various other RapidTip variants that facilitate DNA purification for different applications, such as Sanger sequencing and downstream reactions. Diffinity Genomics serves a diverse clientele, including life science professionals engaged in DNA analysis, as well as industrial and academic research laboratories around the globe. The company utilizes proprietary technology to streamline nucleic acid purification processes, thereby enhancing efficiency in medical, industrial, and research settings.